Ziresovir Triumphs: WHO Adds Chinese RSV Drug to Global Pediatric Priority List
Shanghai’s ArkBio Antiviral Recognized for Urgent Pediatric Need
Shanghai Ark Biopharmaceutical Co., Ltd.’s antiviral drug, ziresovir, has achieved a significant milestone, being named to the World Health Organization’s (WHO) “Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report” priority list. This marks the first time a Chinese-developed RSV antiviral has been included in the WHO’s global pediatric drug development priorities.
Bridging a Critical Global Health Gap
Respiratory syncytial virus (RSV) poses a severe threat to infants and young children worldwide, causing millions of respiratory infections, hospitalizations, and thousands of deaths annually, disproportionately affecting low- and middle-income countries. Recognizing this urgent unmet medical need, the WHO’s Global Accelerator for Paediatric Formulations (GAP-f) project aims to streamline research and development for child-friendly RSV treatments. Ziresovir’s inclusion highlights its potential to address a critical gap in pediatric care.
The WHO acknowledged the substantial clinical value of ziresovir, emphasizing the importance of further diverse clinical studies across broader populations to confirm its efficacy and applicability. This recommendation underscores the drug’s promising profile as a safe and effective option for young patients.
ArkBio Commits to Global Accessibility
In response to the WHO’s endorsement, ArkBio plans to accelerate ziresovir’s clinical development internationally. The company intends to collaborate with global scientific institutions and public health organizations to expedite the drug’s registration and accessibility worldwide. ArkBio is particularly focused on ensuring that low- and middle-income countries, which bear the brunt of RSV mortality, will have access to ziresovir at affordable prices.
“The inclusion of ziresovir in the WHO PADO-RSV priority list is not only an affirmation of the years of effort by ArkBio scientists, but also an inspiration for our corporate mission. The recognition of ziresovir would allow us to expedite its global development and realize the potential on the global stage. We will ensure the innovation can not only benefit patients in China but the very needed patients worldwide. This is not just our goal but our social responsibility. ArkBio will strive to contribute more to address global public health issues.”
—Dr. Jim Wu, CEO of ArkBio
The company’s mission, “to help patients inspire and thrive,” guides its commitment to equitable global health solutions. ArkBio’s strategic approach aims to make its innovations accessible, fulfilling a crucial social responsibility.
Understanding GAP-f and PADO Initiatives
GAP-f, hosted by the WHO, supports the development and dissemination of optimized pediatric drug formulations throughout the product lifecycle. By identifying priority areas, GAP-f helps concentrate research and resources on critical pediatric needs. The PADO (Paediatric Drug Optimization) initiative, a WHO-recognized international priority, fosters collaboration among regulators, funders, and manufacturers to speed up the development of essential pediatric medicines. This framework has previously yielded significant progress in areas such as HIV, hepatitis C, and COVID-19 treatments.
Ziresovir: A Novel Approach to RSV Treatment
Ziresovir is a pioneering small-molecule inhibitor targeting the RSV fusion (F) protein. It functions by binding to the pre-F protein conformation, thereby blocking viral entry into human cells. Furthermore, it can prevent the spread of the virus by inhibiting cell-to-cell fusion, a hallmark of RSV infection. Ziresovir is notable for being the first orally administered RSV antiviral drug to successfully complete a Phase 3 pivotal clinical study, with findings published in leading medical journals. The drug has already received Breakthrough Therapy designation from China’s National Medical Products Administration (NMPA).
ArkBio’s Commitment to Innovation
Founded in 2014, ArkBio is dedicated to developing novel therapeutics for respiratory, infectious, and pediatric diseases. The company has cultivated robust technological platforms and a distinctive research and development pipeline through internal efforts and external collaborations. Beyond ziresovir, ArkBio’s portfolio includes Azstarys (AK0901), an ADHD therapeutic approved by the U.S. Food and Drug Administration (FDA). ArkBio has forged strategic partnerships with prominent entities such as Roche, Genentech, and the Scripps Research Institute, underscoring its commitment to advancing global health.
